The news of RBC Capital maintaining a Sector Perform rating on Vertex Pharmaceuticals and raising the price target from $315 to $323 indicates that the analyst has a neutral outlook on the stock. This may not have a significant short-term impact on the stock price, as the rating remains unchanged. However, the increased price target may provide a slight positive sentiment among investors.